Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.60 USD
Change Today +0.47 / 4.22%
Volume 29.5K
VCYT On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/13/14 - $15.02
52 Week Low
11/14/14 - $6.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the Percepta Bronchial Genomic Classifier, a lung cancer test that would identify patients with non-diagnostic bronchoscopy results whose nodules are at low risk of being cancerous. Veracyte, Inc. serves endocrinologists; radiologists; and ear, nose, and throat physicians. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

167 Employees
Last Reported Date: 03/25/15
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

veracyte inc (VCYT) Key Developments

Veracyte Seeks Acquisitions

Veracyte, Inc. (NasdaqGM:VCYT) has filed a Shelf Registration in the amount of $125.00 million, Veracyte will use the net proceeds from the sale of the securities offered by this prospectus for general corporate purposes. General corporate purposes may include additions to working capital, financing of capital expenditures, repayment or redemption of existing indebtedness, and future acquisitions and strategic investment opportunities.

Veracyte, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 07:30 AM

Veracyte, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 07:30 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: Bonnie H. Anderson, Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee.

Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples

Veracyte, Inc. presented preliminary data demonstrating the ability of the company's molecular classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs) using samples obtained through bronchoscopy. The findings suggest the classifier's potential to help thousands of patients avoid invasive, risky and expensive surgery to resolve ambiguity in IPF diagnosis – a frequent challenge for physicians and patients. The data were presented at the American Thoracic Society (ATS) 2015 International Conference in Denver, Colo. The presentation coincides with online publication in TheLancet Respiratory Medicine of an article detailing foundational work and results from an independent test set, which demonstrated classifier performance using patient tissue samples obtained through surgery. The data shared at ATS demonstrate the ability of a Veracyte molecular classifier to distinguish the presence of a specific pathology pattern that is a hallmark of IPF among samples obtained through transbronchial bronchoscopy (TBB). This pathology pattern – whose presence is essential to IPF diagnosis – is often difficult to distinguish without surgery. Using whole-genome data and classifiers trained by histopathology "truth," researchers developed a classifier that could distinguish this pattern with high specificity (92 percent), suggesting its ability to identify and distinguish IPF from other ILDs, including non-specific interstitial pneumonia, emphysema and organizing pneumonia. Each year in the United States and Europe, up to 200,000 patients are suspected of having an ILD, including IPF, which is the most common and most deadly, and is difficult to diagnose.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $11.60 USD +0.47

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $20.30 USD -2.00
PDI Inc $2.13 USD 0.00
Response Genetics Inc $0.12 USD +0.0019
Rosetta Genomics Ltd $3.07 USD +0.07
Trovagene Inc $7.88 USD +0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at